Trials / Conditions / Dense Deposit Disease

Dense Deposit Disease

14 registered clinical trials studyying Dense Deposit Disease — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127	Apellis Pharmaceuticals, Inc.	Phase 3
Recruiting	Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy NCT04183101	Region Skane	Phase 2
Completed	Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glo NCT03723512	Mario Negri Institute for Pharmacological Research	N/A
Terminated	A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 NCT03459443	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) NCT03369236	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies NCT03453619	Apellis Pharmaceuticals, Inc.	Phase 2
Completed	A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MP NCT03124368	Alexion Pharmaceuticals, Inc.	Phase 2
Withdrawn	TP10 Use in Patients With C3 Glomerulopathy (C3G) NCT02302755	University of Iowa	Phase 1
Terminated	Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease NCT01791686	Celldex Therapeutics	Phase 1
Completed	Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy NCT01221181	Columbia University	Phase 1
Recruiting	National Registry of Rare Kidney Diseases NCT06065852	UK Kidney Association	—
Withdrawn	Sulodexide Treatment in Patients With Dense Deposit Disease NCT00583427	University of Iowa	Phase 1
Approved For Marketing	C3G/Primary IC-MPGN EAP NCT04729062	Apellis Pharmaceuticals, Inc.	—